Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyene phosphatidylcholine ± magnesium isoglycyrrhizinate for perioperative liver injury after laparoscopic hemihepatectomy in hepatocellular carcinoma
ChiCTR2500109064Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of polyene phosphatidylcholine in hepatocellular carcinoma (HCC) and Hepatic injury (not a disease, but a descriptive term for liver damage) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Mean ALT on postoperative day 5. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
polyene phosphatidylcholine
03
Conditions
hepatocellular carcinoma (HCC)Hepatic injury (not a disease, but a descriptive term for liver damage)
Beyond the preview
Go deeper on ChiCTR2500109064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109064.